Thursday, October 27, 2011
The story is still unreeling slowly, but today's New York Times carries another Hiroko Tabuchi article that's worth noting. On Wednesday, Olympus' chairman -- to whom Mr. Woodford had presented his evidence of fraud -- resigned. He regretted "causing concern" to the shareholders (Olympus' share price has fallen by half), and continued to insist that there was "no corruption" in the deal to acquire Gyrus.
Tsuyoshi Kikukawa, who resigned yesterday, had been with Olympus for nearly 50 years, and its chairman for ten. He has been replaced by Shuichi Takayama, a managing director who has been with Olympus for 30 years.
As the Times article notes, the current debacle can be seen "as evidence of still-frequent lapses of corporate governance in a country where truly independent board members are still rare, although there’s a requirement that one director or auditor be independent. And still in force, experts say, is a deep-rooted Japanese business culture in which personal relationships can sometimes seem to take priority over generally accepted accounting practices."
So, is it culture? Or is it ethics? And will it look more like one to us, in the West, and more like the other, to those in Japan?
Wednesday, October 26, 2011
What if you're one of those patients? More hoops, or fewer?
Or if your nifty device doesn't work? Or has side effects you hadn't been aware of?
Different answers, maybe?
Today's New York Times carries an article by Barry Meier and Janet Roberts on the expensive lobbying efforts by venture capital firms to reduce the regulation required to bring new devices to market.
According to the Times article, venture capitalists and device manufacturers "argue that the FDA suffers from high personnel turnover, an unwieldy bureaucracy and a regiment that forces start-up device companies to run new and costly tests constantly, often duplicating past efforts."
But that's only one side of the story, isn't it?
The reporters quote the editor of Archives of Internal Medicine, who said that venture capitalists operate under "this unwritten assumption that every new device is innovative." But the reality, she added, is that some devices "are killing people or causing significant harm."
I've written about more than one of those devices in the past -- the cone-beam CR scanner that may be exposing children and adolescents to excessive radiation (post, here) and the DePuy hip replacements whose metal-on-metal design is failing early far too often, requiring painful and extensive additional surgery (post, here).
The House seems more interested in the manufacturers' and investors' concerns, however:
Since February, four House panels have held hearings on the impact of FDA procedures on device approval. At those sessions, 19 of the 26 listed witnesses were investors, entrepreneurs, industry consultants, trade group officials or patients who said that agency delays in approving a device had harmed them or a loved one. The list included no patients injured by a flawed device; one hearing the Senate had a more varied witness list. [emphasis added]One investment fund manager is quoted as saying, "This is about survival... We are deeply concerned about the future."
Shouldn't they be "deeply concerned" about the "survival" of their patients?
Tuesday, October 25, 2011
Indeed, that's how it was presented. As the New York Times' Hiroko Tabuchi reported (full story, here), Olympus' chairman said, "We hoped that he could do tings that would be difficult for a Japanese executive to do... But he was unable to understand that we need to reflect a management style we have built up in our 92 years as a company, as well as Japanese culture."
Isn't that a fascinating comment? In other words, Olympus wanted a CEO who was un-Japanese, but not too un-Japanese. How's that for a recipe for failure? (Michael Woodford, the ousted CEO, was British, but had spent 30 years with Olympus, so you'd think he would have a pretty good handle on Japanese culture.)
Share prices in Olympus dropped dramatically on the news of the CEO's demotion.
They declined further two days later, when Mr. Woodford claimed that he was forced out because he had presented the Olympus chairman with evidence of fraud. (Article by Hiroko Tabuchi here)
As further explained a few days later by the Times' Wayne Arnold and John Foley (full story, here), Mr. Woodford said that "he was forced out after pointing out governance problems surrounding overseas acquisitions, in particular a $1.9 billion deal for Gyrus, a British medical equipment firm. He accuses [sic] the board of violating British law against paying a buyer for an acquisition, false accounting and breach of fiduciary duties."
So now it appears not to be a cultural issue at all, but an ethical and legal one. Were Japanese laws allegedly violated as well? Or only British laws?
The heart of the conflict, as reported yesterday by the Times' DealBook reporter, Ben Protess, is "a mysterious $687 million payout" made by Olympus to two formerly-unknown Japanese bankers (full story, here). That payout was originally described as a "fee" for advising Olympus on the 2008 Gyrus takeover. But, as Protess notes, that payout is "more than 30 times the norm on Wall Street" -- and Wall Street is not generally known for underpaying itself.
Protess also reported that "the FBI is now investigating the $687 million payment... The focus of the investigation is not yet clear, and a spokesman for the FBI ...declined to comment."
So now there are American laws that may have been broken, too?
Protess quotes Jeffrey Manns, an associate professor at George Washington University Law School: "This is such an extraordinary deviation from normal fees.... No one would have entered into this transaction if they were showing good business judgment."
Olympus, of course, insists that the payment was "appropriate".
It's far too early to know whether this is primarily a cultural clash or an ethical (and legal) breach; the mess may well end up having elements of both, and those elements may be closely intertwined. Either way, there's an ugly smell hanging over a once-admired firm.
Monday, October 17, 2011
"Online Banking Keeps Patrons Tangled in Fees" wrote Nelson Schwartz in the first. In the second, "The Haggler" (columnist David Segal) investigated the questionable practices of Synapse Group, a magazine subscription firm that "is skilled at signing up subscribers but miserable at alerting them later that their subscriptions are being renewed. So bad that a plaintiff’s lawyer, Gary Graifman, filed a class-action lawsuit against it, contending that it purposely tries to make its renewal notices look like junk mail."
At first glance, these don't seem related, do they? But consider one example from Schwartz's story:
Tedd Speck, a 49-year-old market researcher in Kent, Conn., was furious about Bank of America’s planned $5 monthly fee for debit card use.
But he is staying put after being overwhelmed by the inconvenience of moving dozens of online bill paying arrangements to another bank.
“I’m really annoyed,” he said, “but someone at Bank of America made that calculation and they made it right.”
In other words, the bank has made it as difficult as possible to "unsubscribe". Meanwhile, what did the plaintiff's lawyer say about Synapse's practices?
“You subscribe to, say, Sports Illustrated, but you get a notice from a company called Synapse, which no one has ever heard of,” says Mr. Graifman, of the New York law firm Kantrowitz, Goldhamer & Graifman. “The whole game is to discourage as many people as possible from canceling, and these guys are very sophisticated about how they do that.”
He sent a copy of the renewal notice that Synapse sends to customers. The front reads: “Less time at the newsstand means more time enjoying your favorite magazines.” Next to that is: “Subscriber rate enclosed. Up to 40 percent off newsstand prices.”
If that doesn’t say “Toss me, I’m junk mail,” what does?
If you do toss that piece of "junk mail", you will shortly discover that by not replying, you have "permitted" Synapse to bill your credit card automatically for renewals. In other words, they've made it as difficult as possible to unsubscribe. The original complainer to The Haggler had forwarded the company phone number that had been listed on her credit-card bill; if you do call the number, what you get is "only an automated voice routine, not a human being."
In neither of these cases does the company care about customer satisfaction. They define loyalty as "gotcha".
Meanwhile, on Synapse's website, the home page extols the company's "values" and "social responsibility". Synapse, of course, doesn't really care about you, the magazine reader who can't get out of your subscription. It cares about the magazine, which has hired it to keep you on the hook (Synapse is a wholly-owned subsidiary of Time Inc.). Synapse is particularly proud of its patented "magazine subscription model, Continuous Service." And what is Continuous Service? It's a model that
eliminates the inefficiencies and inconveniences of the traditional model, and replaces it with a solution that meets the needs of today's harried consumer. Today, tens of millions of subscribers enjoy the simplicity and superior experience of continuous service.
Sounds exactly like what the plaintiff's attorney was describing, doesn't it?
The banks, meanwhile, will trill away about how much easier it is for you to have all your accounts at one bank, and to pay your bills online. They will not tell you that "using the Internet to pay bills, do automatic deductions and send electronic checks reduced customer turnover for banks by up to 95 percent in some cases." Even if you're deeply dissatisfied, the thought of having to change all those accounts is daunting.
Every business wants to hold onto its customers, of course. The question is, Are you being truthful and transparent about how you're holding on to them?